Comprehensive gene analysis for tumor immunotherapy of pancreatic cancer and prediction of therapeutic efficacy.

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K08418
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 53010:Gastroenterology-related
• Research Institution: University of Yamanashi
• Principal Investigator: Fukasawa Mitsuharu 山梨大学, 大学院総合研究部, 特任講師 (00377508)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 膵癌 / EUS-FNA / 個別化医療

Outline of Final Research Achievements

Identification of therapeutic targets and selection of individualized therapeutic agents are important to improve the prognosis of pancreatic cancer. In this study, we examined the analysis of EUS-FNA samples, which are important for the selection of novel therapies for pancreatic cancer, such as molecular targeted drugs and immune checkpoint inhibitors that have recently emerged. The required EUS-FNA specimen volume was more than 3 ng of DNA, and rapid pathology was useful to achieve this. Genetic analysis showed that 20% of patients had genetic abnormalities that could be markers for FDA-approved molecular-targeted drugs, and 14% of patients had abnormalities in HRR-related genes that could be markers for FOLFIRINOX, which is used in actual clinical practice. Analysis of prognosis-related genetic abnormalities was also possible.

Free Research Field

消化器内科学

Academic Significance and Societal Importance of the Research Achievements

膵癌の予後延長に期待が持たれる個別化医療であるが、その障害となりうる組織採取において、膵癌で通常行われるEUS-FNAという検体採取法で遺伝子解析が十分可能という結果を得た。本研究からも治療標的になりうると考えられる遺伝子異常が多数得られたが、今後は検索する遺伝子の範囲を適正化し、さらなる精度の向上を検討する足掛かりとなった。